Table 17. Summary of HIEPC-related procedures in different PC institutions or countries (published researches).
Country /No. Institutions |
Major Institutions | No. patients | Mode | HIPEC-MMC alone | HIPEC-MMC+DDP | HIPEC-L-OHP alone | HIPEC-other | Temperature (°C) |
Duration (min) |
---|---|---|---|---|---|---|---|---|---|
Spain, 6 | M. D. Anderson Cancer Center [29, 71] | ||||||||
Subtotal/Median/Range | ? | O/C | Y | Y | 40-43 | 30-120 | |||
San Jose Hospital [29, 71] | |||||||||
Subtotal/Median/Range | ? | O/C | Y | Y | 40-43 | 30-120 | |||
Hospital Infanta Cristina [71] |
? | O/C | Y | Y | others | 40-43 | 30-120 | ||
Hospital Santiago Apostol [13] | 25 | O/C | Y | Y | Y | MMC+CPT-11, 5-FU | 40-43 | 30-90 | |
Subtotal | >25 | O/C | Y | Y | MMC+CPT-11, 5-FU | 41.5 (40-43) | 90 (30-120) /30 | ||
Canada, 2 | University of Calgary [56, 66, 68, 73] | ||||||||
Subtotal/Median/Range | 375 | O | 12-15 mg | 400 mg/m2 | 41.5 (40-42) | 60 | |||
Maisonneuve-Rosemont Hospital, University of Montreal [14, 38, 53] | |||||||||
Subtotal/Median/Range | >40 | O | 30-50 mg/m2 | 30-50 mg/m2 + 50-100 mg/m2 | 360-460 mg/m2 | L-OHP (360-460 mg/m2) + CPT-11 (100-200 mg/m2) | 41.5 (41-42.5) /43 (42-43) | 90 (60-120) /30 or 60 | |
Subtotal | >415 | O | 12-15 mg /30-50 mg/m2 | 30-50 mg/m2 + 50-100 mg/m2 | 360-460 mg/m2 | L-OHP + CPT-11 | 41.5 (41-42.5) /43 (42-43) | 60 or 90 (60-120) /30 or 60 | |
Greece, 2 | Metaxa Cancer Memorial Hospital [29, 71] | ||||||||
Subtotal/Median/Range | ? | O/C | Y | Y | 40-43 | 30-120 | |||
Didimotichon General Hospital [13] | 25 | O/C | Y | Y | Y | MMC+CPT-11, 5-FU | 40-43 | 30-90 | |
Subtotal | >25 | O/C | Y | Y | Y | MMC+CPT-11, 5-FU | 41.5 (40-43) | 30-90 | |
Australia, 1 | St. George Hospital [15, 26, 29, 34, 41, 45, 64, 72, 81, 90, 91] | ||||||||
Subtotal | >618 | O | 10-12.5 mg/m2 | 350 mg/m2 | 42 | 90 or 30 |
Note: C: closed abdomen technique for HIPEC; O: open abdomen technique for HIPEC; Y: yes; MMC: mitomycin C; DDP: cisplatin; 5-FU: fluorouracil; L-OHP: oxaliplatin; CPT-11: irinotecan